The OTC bear market hasn’t gone away; however, this too shall pass. We’ve been here before and will be here again no matter what happens. Markets go in cycles and OTC stocks aren’t immune. Matter of fact, the OTC probably sees more bull and bear markets in a year than any other market.
OTC investors are failing to realize that there are still plenty of opportunities on the OTC Markets. Continuing to buy the dips in losers is not a winning strategy. We tell our subscribers to focus on what’s working and ignore the noise. Don’t get caught up in the diamond hands/paper hands BS. We talk about all of this in the video below.
In this article, we look at 4 OTC stocks making waves, including Indo Global Exchange(s) Pte Ltd/The Mineral Company Pte LTD (OTCPK: IGEX), Nitches Inc (OTCPK: NICH), NuGene International, Inc (OTCPK: NUGN), and Northwest Biotherapeutics, Inc (OTCPQB: NWBO).
OTC STOCKS #1 IGEX
Indo Global Exchange(s) Pte Ltd, which is now known as The Mineral Company Pte LTD, has experienced a volatile start to the month, with the OTC stock rebounding from a bottom in March, when it touched the lowest since May 2021 at $0.0022. The price has quadrupled since then, currently trading above $0.008, after breaking the penny mark on Tuesday.
The $40 million company is not a shell anymore, as the symbol has been removed, and IGEX got the Pink Current designation. During the last few weeks, IGEX has completed two acquisitions of assets to accelerate its operations in the lithium and graphene industries:
- In January, it purchased a 50,000 sqm lot located in Jumilla, Spain, for a total of €300,000 plus approximately an 11% RE tax assessment. The property is worth almost 1 million euro as reported independently by ‘Arquitasa’, which has been homologated by Banco de España.
- In February, IGEX acquired water rights over the above reference lots, underground reservoirs, and an existing extraction station, including 2 industrial water pumps for a total of €100,000.
The two acquisitions are essential to the success of the anticipated merger between IGEX, a well-established leader in lithium and energy storage, and a Spanish company involved primarily in the graphene manufacturing industry. The assets acquired by IGEX and the merger are essential to the successful development of the premier center for manufacturing, storage, and shipping of minerals with an emphasis on lithium, graphene, and its derivatives in Southern Europe. Retained engineers and architects are already working on finalizing all necessary plans and permits with the goal to break ground in less than 6 months, aiming at having the first phase of the project completed and operational by the end of 2022.
Lithium is currently one of the hottest markets, as lithium-ion is the leading technology in the electric vehicle industry. The global lithium market was valued at more than 400 LCE kiloton in 2021, and the market is expected to grow at a CAGR of almost 20% from 2022 to 2027.
IGEX has a decent share structure, is testing key resistance at the one penny mark, and is a short squeeze candidate. When it starts its operations in the lithium and graphene markets, the OTC stock can grow exponentially.
— $py Sniper ATL (@ATL_EN) April 12, 2022
OTC STOCKS #2 NICH
Nitches Inc is also rebounding after finding strong support in mid-March. The Pink Current stock has gained almost 18% over the last five days to trade at $0.17. On Monday, the share price peaked at $0.34 on record volumes. NICH rallied in January-February when it broke above the $0.70 mark for the first time in over five years, but it quickly lost momentum until bottoming out in mid-March at less than $0.09.
NICH is a diversified company that specializes in creating merchandise and manufacturing high-end luxury brands, goods, and collectibles for influencers and celebrities. Nitches is focused on sports clothing, athleisure brands, sustainable products, non-fungible tokens (NFTs), and tech solutions.
Besides its merchandise and manufacturing operations, Nitches is partnering with brands that are innovating outside of the box.
The recent bounce started after NICH announced that 189 million of common shares (about 80%) were in the process of being returned and cancelled, which reduces the company’s outstanding common shares to 39,659,644 from 229,659,644. CEO John Morgan said:
“Nitches continues to diligently protect the value of our common stock for shareholders. Our company takes great pride in being an excellent corporate citizen and conducting ourselves with exemplary integrity and ethics in our business and relations with all stakeholders.”
The company is also negotiating to cut some of its debt to a more standard note of a 50% discount to the market.
Earlier in April, NICH announced the grand opening of its online stores that are selling limited-edition hoodies and caps. The luxury athleisure items are part of Superstar Vocal Coach Nick Cooper’s ‘FutureMega’ collection and The ‘BadAss Vegan’ Influencer and Filmmaker John Lewis’ ‘Peace on Marz’ line. Consumers can buy these items by visiting the stores on nitchescorp.com.
Nitches also minted 250 NFTs of each of the hoodies and hats to be used by buyers as digital art and collectible. After products are purchased and received, buyers can register and authenticate them using Nitches’ Owner Verification System (OVS™).
NICH works one-on-one with entertainers and influencers during each step of the process, from design to production, to develop superior quality products that represent their values and brands. The company is currently in talks with other celebrities about future capsule collections.
On Tuesday, the company said it would design and manufacture its own exclusive clothing and merchandise to promote positive thinking and mindfulness.
A few hours before the close of the Tuesday session, the company tweeted that it was exploring metaverse.
— Nitches (@nitchescorp) April 12, 2022
Investors haven’t reacted to this hint yet, but we think NICH is an OTC stock that you should watch closely given its growth potential.
OTC STOCKS #3 NUGN
NuGene International, Inc is making waves, trading at the highest level in almost five years. The Pink Current stock has surged by over 230% over the month to trade at $0.135.
Last month, NUGN announced the completion of a change in control with Livento Group LLC, a Delaware Corporation. Livento CEO David Štýbr acquired majority voting control in a private transaction with Milan Hoffman, CEO of Emergent LLC, a majority holder in NUGN. Following the deal, Livento changed the company’s business model, with NUGN currently focusing on the film and television industry. Livento currently has contracts with a production company that produces films for Netflix and Prime Video and co-producing large budget films worldwide with top actors in the film industry. To date, they have produced and co-produced sixteen films on Netflix, the latest of which was released September 3.
Besides the film industry, Livento is specializing in the development and growth of disruptive business models. It has proprietary artificial intelligence (AI) and machine learning products that incorporate risk analysis, predictive maintenance, and operational forecasting into its decision-making process. Its main areas of focus are real estate development in rapidly developing European cities, and the production of premium film and television content for European and international audiences across multiple genres.
On Monday, NUGN announced the launch of BOXO Productions, its new film and television production subsidiary. The BOXO leadership team is led by industry heavyweights actor/producer Petr Jákl, former CAA agent Ara Keshishian and producer Martin J. Barab. The BOXO team has already amassed a catalog of star-studded, award-winning movies featuring Hollywood legends and Oscar winners like Al Pacino, Michael Caine, John Malkovich, Samuel L. Jackson, Pierce Brosnan, Ed Harris, and others. Several major projects are in the pipeline of the company, including films starring Johnny Depp, Morgan Freeman, Cate Blanchett, Nicole Kidman, Gwyneth Paltrow, Edward Norton, Christian Bale, Brad Pitt, Bradley Cooper, Scarlett Johansson, and Dustin Hoffman, amongst many others.
— Emergent LLC (@EmergentLlc) April 11, 2022
“We expect to generate approximately $50 million in global box office sales per movie over the next 3 years.”
With a production target of 6 Hollywood movie releases per year, BOXO is expected to bring an exponential increase in cash flow to NUGN.
With a market cap of only $24 million and a decent share structure, this stock is only getting started and may hit the $1 mark very soon. This is really a big buy – how many OTC companies expect $300 million in revenues per year and are associated with names like Al Pacino, Brad Pitt, and Johnny Depp?
OTC STOCKS #4 NWBO
Northwest Biotherapeutics, Inc is the only OTCQB member on our list. The stock has gained over 30% during the last five sessions alone, which is significant for a company with a market cap close to $1 billion. The biotech firm has some strong fundamentals, and we have covered it on several occasions. We first reported on Northwest Biotherapeutics in September 2020, well before the price surge that led to the highest level in years at over $2. Now you can buy the stock for almost $1, which is a key resistance level that puts pressure on bulls.
NWBO develops personalized immune therapies for cancer in the US and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. It also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.
At the end of October, the company said that it had completed two key milestones which are required for the production of DCVax products at its manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.
The full results of NWBO’s Phase 3 trial may be released in the coming weeks, and investors are quite optimistic about them, forcing a rebound in the OTC stock from its recent bottom below $0.70. This may be a turning point for Cancer treatment and for NWBO itself.
At the 2022 AANS annual scientific meeting held in Philadelphia, Dr. Linda Liau, Dr. Steven Brem, and Dr. Roger Stupp will discuss “New Science & Clinical Trials That Will Change Glioblastoma Management in the Next Five Years.”
“NEW Science & Clinical Trials That Will Change Glioblastoma Management in the Next Five Years”
— 🇺🇸🤝🇺🇦eastvillagetwt (@eastvillagetwt) April 12, 2022
Given that Dr. Steven Brem, Director of Neurosurgery at the University of Pennsylvania, was one of the investigators on the DCVax-L Phase III trial, the upcoming event may have some important revelations about NWBO’s Phase 3 trial, and this may push the share price to new highs.
NWBO is a smart investment with long-term potential. The results of Phase 3 will make all the difference.
THE FINAL NOTE
All of the 4 OTC stocks discussed today are good stocks to own. The upside is much greater than the downside at these levels.
It’s also very important to eye OTC stocks that have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.